Clamp Study
Conditions
Keywords
Pharmacokinetics, Pharmacodynamics, Insulin Lispro
Brief summary
Pharmacokinetics and pharmacodynamics study Study of 2 formulation of insulin lispro (Insulin Lispro GEROPHARM vers. Humalog® Eli Lilly)
Detailed description
A randomized duble blinded two-way crossover single-dose pharmacokinetics and pharmacodynamics study of Insulin Lispro (LLC GEROPHARM, Russia) versus Humalog® (Eli Lilly) in normal healthy subjects using the euglycemic clamp technique
Interventions
DRUGInsulin Lispro
DRUGHumalog®
Sponsors
Geropharm
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This study was blinded for Sponsor, investigators and analytical laboratory
Intervention model description
two-way crossover
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Signed informed consent. 2. Caucasian males having a confirmed healthy diagnosis as per data of standard clinical, laboratory, and instrumental examination methods. 3. Age of 18-50 (both incl.). 4. Body mass index equal to 18.5-27.0 kg/m2. 5. Volunteers' consent to all restrictions imposed during the study, including adequate methods of contraception.
Exclusion criteria
1. Acute inflammatory diseases within 3 weeks before the screening period 2. Episodes of hypoglycemia in the anamnesis, or the presence in the family history of cases of a verified diagnosis of diabetes mellitus in the immediate family 3. Fasting plasma glucose\> 6.1 mmol / L 4. HbA1C\> 6% 5. Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after loading with glucose) 6. Deep vein thrombosis of lower extremities in a history of life or in a family history. 7. Nicotine dependence (use of tobacco less than 6 months before the start of screening) 8. Taking medications, phytopreparations, biologically active supplements less than 14 days before screening 9. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information about alcoholism. 10. Donor blood donation in excess of 450 ml, less than 2 months before the study. 11. Participation in a clinical trial of any medications less than 3 months before the start of screening 12. Positive test results for hepatitis C or hepatitis B, HIV, syphilis. 13. Anamnesis information about drug and / or drug dependence and / or substance abuse. 14. Positive test for alcohol content in the exhaled air. 15. A positive test for the content of drugs in the urine. 16. Presence of suspicions of an inflammatory disease of the urinary system as a result of urinalysis. 17. Presence of mental illnesses in the anamnesis. 18. Mental, physical and other reasons that do not allow to adequately assess their behavior and properly fulfill the conditions of the research protocol. 19. Any other conditions that make it difficult, according to the informed opinion of the investigating physician, that volunteer participation in studies 20. Increased sensitivity in the history of heparin, insulin or any of the excipients of the study drugs 21. Weighed allergic anamnesis 22. Abnormalities of the ECG and laboratory parameters from the norms 23. Deviations in basic vital signs: systolic blood pressure is below 100 mm Hg. or above 130 mm Hg, the diastolic blood pressure is below 70 mm Hg. or above 90 mm Hg; heart rate less than 60 or greater than 80 24. Deviations in basic vital signs: systolic blood pressure \<100 mmHg. or\> 130 mm Hg, diastolic blood pressure \<70 mm Hg. Art. or\> 90 mm Hg. Art. heart rate \<60 or\> 80 per minute.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | -60, -30 and 0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose | Pharmacokinetics of insulin lispro by Assessment of Observed Maximum Plasma Concentration (Cmax) |
| AUC(0-t) | -60, -30 and 0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose | Pharmacokinetics of insulin Lispro by Assessment of Area Under the Curve From Time Zero Extrapolated to t (AUC(0-t)) |
| GIRmax | 0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose | Pharmacodynamic of insulin lispro by Maximum Glucose Infusion Rate (GIRmax) |
| AUCGIR0-t | 0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose | Pharmacodynamic of insulin Lispro by Assessment of GIR Area Under the Curve From Time Zero Extrapolated to t (AUC(0-t)) |
Countries
Russia
Outcome results
None listed